(Q33332751)

English

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Manegold

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

U Gatzemeier

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J von Pawel

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R Pirker

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R Malayeri

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J Blatter

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

K Krejcy

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

435-440

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Promising new agents in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008336931378

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008336931378

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33332751&oldid=1980959777"